 --Sabizabulin is a novel oral androgen receptor transport disruptor-- -- In Phase 1b2 clinical study, sabizabulin was well tolerated with significant antitumor efficacy in metastatic castration resistant prostate cancer patients who have also become resistant to abiraterone or enzalutamide, but prior to IV chemotherapy-- --Phase 3 clinical study will be conducted in 45 clinical centers across the United States-- MIAMI, June 25, 2021 GLOBE NEWSWIRE -- Veru Inc. NASDAQ: VERU, an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, today announced that it has enrolled the first patient in its Phase 3 VERACITY clinical trial of sabizabulin, an oral, first-in-class, new chemical entity, androgen receptor transport disruptor targets and inhibits microtubules to disrupt androgen receptor transport into the nucleus, for metastatic castration and androgen receptor targeting agent resistant prostate cancer. 